Diarrhorea
Some selected abstract: |
|
1 |
Barennes H, Balima-Koussoube T, Nagot N, Charpentier JC, Pussard E. Safety and efficacy of rectal compared with intramuscular quinine for the early treatment of moderately severe malaria in children: randomised clinical trial. BMJ. 2006 May 6;332(7549):1055-9.
Centre MURAZ, 01BP390 Bobo-Dioulasso, Burkina Faso. hubert.barennes@auf.org
OBJECTIVE: To compare the safety and efficacy of quinine given by the rectal route with quinine given by the intramuscular route in children with moderately severe Plasmodium falciparum malaria. DESIGN: Randomised, open, clinical trial. SETTING: Health centre in Burkina Faso. PARTICIPANTS: 898 children with moderately severe P falciparum malaria who were unable to take oral treatment. INTERVENTION: Rectal quinine (20 mg/kg diluted to 30 mg/ml in water solution) or intramuscular quinine (12.5 mg/kg) every 12 hours until oral quinine could be taken. MAIN OUTCOME MEASURES: Primary safety outcome was the presence of blood in stools and secondary safety outcome was diarrhoea. Primary efficacy outcome was early treatment failure and secondary efficacy outcomes were late clinical and parasitological failures, fever clearance time, and time to oral intake. RESULTS: Blood in stools and diarrhoea were more common in children given quinine by the rectal route than by the intramuscular route (blood in stools: 5% v 1%, absolute difference 3.9%, 95% confidence interval 1.8% to 6.1%; diarrhoea: 5% v 1%, 3.5%, 1.3% to 5.7%). On anoscopy, inflammatory lesions (9/248, 3%) were associated with bloody striations in stools. Side effects of rectal quinine were rare and transitory. Local pain (90%), inflammation (79%), and transient impairment of mobility (15%) were observed with intramuscular quinine. Early treatment failure was higher in the rectal group (6% v 3%, absolute difference 3.0%, 95% confidence interval 0.2% to 5.9%). All except two children in each group had negative blood slide results at day 5. Fever recurrence at day 7 was higher in the intramuscular group (37/375 v 18/395, absolute difference 5.3%, 1.6% to 8.9%). Other efficacy outcomes (late clinical failure, late parasitological failure, fever clearance time, time to starting oral intake and rate of deterioration to severe malaria) did not differ. CONCLUSION: Quinine given by the rectal route has an acceptable safety profile and could be used in the early management of moderately severe malaria in children in sub-Saharan Africa, halting progression to severe disease.
|
2 |
Hill DR, Ford L, Lalloo DG. Oral cholera vaccines: use in clinical practice. Lancet Infect Dis. 2006 Jun;6(6):361-73. Review.
National Travel Health Network and Centre, London, UK. david.hill@uclh.org
Cholera continues to
occur globally, particularly in sub-Saharan Africa and Asia. Oral cholera
vaccines have been developed and have now been used for several years,
primarily in traveller populations. The licensure in the European Union of
a killed whole cell cholera vaccine combined with the recombinant B
subunit of cholera toxin (rCTB-WC) has stimulated interest in protection
against cholera. Because of the similarity between cholera toxin and the
heat-labile toxin of Escherichia coli, a cause of travellers' diarrhoea,
it has been proposed that the rCTB-WC vaccine may be used against
travellers' diarrhoea. An analysis of trials of this vaccine against
cholera (serotype O1) shows that for 4-6 months it will protect 61-86% of
people living in cholera-endemic regions; lower levels of protection
continue for 3 years. Protection wanes rapidly in young children. Because
the risk of cholera for most travellers is extremely low, vaccination
should be considered only for those working in relief or refugee settings
or for those who will be travelling in cholera-epidemic areas and who will
be unable to obtain prompt medical care. The vaccine can be expected to
prevent 7% or less of cases of travellers' diarrhoea and should not be
used for this purpose. |
Therapy: 14703. Boran P, Tokuc G, Vagas E, Oktem S, Gokduman MK. Impact of zinc supplementation in children with acute diarrhoea in Turkey. Arch Dis Child. 2006 Apr;91(4):296-9. |